$15.15
0.845.87%
At Close: -
$14.81
-0.34-2.24%
After Hours: 4:03 PM EDT
15 minutes delayed
Comments
Loading...
Olema Pharmaceuticals
OLMANASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Olema Pharmaceuticals (NASDAQ:OLMA) Stock, Analyst Ratings, Price Targets, Forecasts
Olema Pharmaceuticals inc has a consensus price target of $21.14 based on the ratings of 7 analysts. The high is $30 issued by HC Wainwright & Co. on June 4, 2024. The low is $16 issued by Canaccord Genuity on July 6, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 4, 2024, May 15, 2024, and May 9, 2024, respectively. With an average price target of $29.33 between HC Wainwright & Co., there's an implied 98.06% upside for Olema Pharmaceuticals inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Goldman Sachs
Oppenheimer
Citigroup
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Olema Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/04/2024 | Buy Now | 102.57% | HC Wainwright & Co. | Emily Bodnar | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 102.57% | HC Wainwright & Co. | Emily Bodnar | → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 89.06% | HC Wainwright & Co. | Emily Bodnar | $25 → $28 | Maintains | Buy | Get Alert |
| 04/02/2024 | Buy Now | 62.05% | Goldman Sachs | Richard Law | → $24 | Initiates | → Buy | Get Alert |
| 03/12/2024 | Buy Now | 41.8% | Oppenheimer | Matthew Biegler | $21 → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 68.8% | HC Wainwright & Co. | Emily Bodnar | $28 → $25 | Maintains | Buy | Get Alert |
| 01/30/2024 | Buy Now | 35.04% | Citigroup | Yigal Nochomovitz | → $20 | Initiates | → Buy | Get Alert |
| 10/11/2023 | Buy Now | 89.06% | HC Wainwright & Co. | Emily Bodnar | → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 28.29% | JP Morgan | Anupam Rama | $16 → $19 | Maintains | Overweight | Get Alert |
| 09/06/2023 | Buy Now | 41.8% | Oppenheimer | Matthew Biegler | → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 09/05/2023 | Buy Now | 89.06% | HC Wainwright & Co. | Emily Bodnar | $22 → $28 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 8.04% | JP Morgan | Anupam Rama | $14 → $16 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | 21.54% | Credit Suisse | Richard Law | $16 → $18 | Maintains | Outperform | Get Alert |
| 08/09/2023 | Buy Now | 48.55% | HC Wainwright & Co. | Emily Bodnar | $17 → $22 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | 41.8% | Oppenheimer | Matthew Biegler | → $21 | Initiates | → Outperform | Get Alert |
| 05/11/2023 | Buy Now | 14.79% | HC Wainwright & Co. | Emily Bodnar | $14 → $17 | Maintains | Buy | Get Alert |
| 03/10/2023 | Buy Now | -25.73% | Credit Suisse | Richard Law | $12 → $11 | Maintains | Outperform | Get Alert |
| 03/10/2023 | Buy Now | 1.28% | HC Wainwright & Co. | Emily Bodnar | $12 → $15 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | -18.97% | Credit Suisse | Richard Law | → $12 | Initiates | → Outperform | Get Alert |
| 07/06/2022 | Buy Now | 8.04% | Canaccord Genuity | William Maughan | → $16 | Assumes | → Buy | Get Alert |
| 06/10/2022 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar | — | Upgrade | Neutral → Buy | Get Alert |
| 02/28/2022 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Olema Pharmaceuticals (OLMA) stock?
The latest price target for Olema Pharmaceuticals (NASDAQ:OLMA) was reported by HC Wainwright & Co. on June 4, 2024. The analyst firm set a price target for $30.00 expecting OLMA to rise to within 12 months (a possible 102.57% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Olema Pharmaceuticals (OLMA)?
The latest analyst rating for Olema Pharmaceuticals (NASDAQ:OLMA) was provided by HC Wainwright & Co., and Olema Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Olema Pharmaceuticals (OLMA)?
The last upgrade for Olema Pharmaceuticals inc happened on June 10, 2022 when HC Wainwright & Co. raised their price target to N/A. HC Wainwright & Co. previously had a neutral for Olema Pharmaceuticals inc.
When was the last downgrade for Olema Pharmaceuticals (OLMA)?
There is no last downgrade for Olema Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Olema Pharmaceuticals (OLMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Olema Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Olema Pharmaceuticals was filed on June 4, 2024 so you should expect the next rating to be made available sometime around June 4, 2025.
Is the Analyst Rating Olema Pharmaceuticals (OLMA) correct?
While ratings are subjective and will change, the latest Olema Pharmaceuticals (OLMA) rating was a reiterated with a price target of $30.00 to $30.00. The current price Olema Pharmaceuticals (OLMA) is trading at is $14.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.